Iovance Biotherapeutics Inc investor relations material
Listen to the latest call from Iovance Biotherapeutics Inc
Iovance Biotherapeutics (NASDAQ: IOVE) is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Our lead candidate, Poziotinib, is an orally administered small molecule inhibitor that targets the ABL kinase family with broad spectrum kinase inhibitory activity including sensitivity to low plasma concentrations of inhibitors.
Ticker
IOVACountry
USAbout
IR-page